IBM & Broad Institute Launch Major Research Initiative

CAMBRIDGE, MA - 10 Nov 2016: IBM Watson Health (NYSE: IBM) and the Broad Institute of MIT and Harvard today announced a research initiative aimed at discovering the basis of cancer drug resistance. The five year, $50 million project will study thousands of drug resistant tumors and draw on Watson's computational and machine learning methods to help researchers understand how cancers become resistant to therapies. The anonymized data will be made available to the scientific community to catalyze research worldwide. IBM Watson Health and the Broad Institute bring the data prowess of Watson to study cancer drug resistance in a $50M research collaboration. The goal is to identify patterns that could reveal clues into one of the greatest medical mysteries of cancer.